BioSpace News Archive

Aldeyra Therapeutics, Inc. today announced positive top-line results from the Phase 2 clinical trial of orally administered ADX‑629, an investigational new drug, in patients with chronic cough.

Alpha Healthcare Acquisition Corp. III announced the execution of a non-binding letter of intent to acquire a commercial stage regenerative medicine company conditioned upon the closing of ALPA’s initial business combination with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications.

Arch Biopartners Inc. announced today that it received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) for a Phase II human trial for LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI).

KORU Medical Systems, Inc. today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023.

Harpoon Therapeutics, Inc. today announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the safety, tolerability, and pharmacokinetics of HPN217 in patients with relapsed/refractory multiple myeloma.

Anavex Life Sciences Corp. and Partex N.V. Group, the first Data-to-Drugs digital pharma platform, announced a strategic partnership with the overall ambition to reshape the future of the biopharma business model.

CENTOGENE N.V. and Lifera today announced a strategic collaboration with the formation of a Joint Venture (JV) to increase local and regional access and rapid delivery of world-class multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council (GCC).

Cybin Inc. is pleased to announce that Mr. Sanford R. Climan has joined Cybin as a strategic advisor.

Annovis Bio, Inc. announces the creation of a novel crystalline form of buntanetap (ANVS402), and the filing of a new composition of matter provisional patent with the U.S. Patent and Trademark Office.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to initiate a Phase 1 clinical trial of ARO-SOD1.